Incretin Atlas › Trials › ACCESS (phase 2b)
ACCESS (phase 2b)
Aleniglipron · obesity
Design
- Molecule(s)
- Aleniglipron
- Population
- obesity
- Phase
- 2
- Participants
- 65
- Duration
- 36 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aleniglipron 45 mg | obesity | 36 | 45 | −9.0 % vs −0.8 % Δ −8.2 pp | −8.8 % vs −1.0 % Δ −7.8 pp | −0.3 vs +0.0 | 13.3 vs 5.4 | 26.7 vs 25.0 | 71.1 vs 21.4 | 40.0 vs 5.4 | 2.2 vs 5.4 | −7.9 vs −1.5 | verified |
| aleniglipron 90 mg | obesity | 36 | 65 | −10.7 % vs −0.8 % Δ −9.9 pp | −10.2 % vs −1.0 % Δ −9.2 pp | −0.3 vs +0.0 | 7.7 vs 5.4 | 24.6 vs 25.0 | 67.7 vs 21.4 | 44.6 vs 5.4 | 0.0 vs 5.4 | −8.9 vs −1.5 | verified |
| aleniglipron 120 mg | obesity | 36 | 64 | −12.1 % vs −0.8 % Δ −11.3 pp | −11.4 % vs −1.0 % Δ −10.4 pp | −0.4 vs +0.0 | 11.1 vs 5.4 | 21.9 vs 25.0 | 65.1 vs 21.4 | 31.7 vs 5.4 | 6.3 vs 5.4 | −9.0 vs −1.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- aleniglipron 45 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
- aleniglipron 90 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
- aleniglipron 120 mg: Oral, once daily; titration from 5 mg every 4 weeks. Pooled placebo. Treatment-policy column = the paper's «treatment regimen estimand».
Verbatim quotes from the source (27)
- aleniglipron 45 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 45 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 45 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 45 mg · disc_any · Fig. 1 CONSORT
33 (73.3%) Completed treatment (week 36) 12 (26.7%) Discontinued study treatment 6 (13.3%) Adverse event
- aleniglipron 45 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 45 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 45 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 45 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 45 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
- aleniglipron 90 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 90 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 90 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 90 mg · disc_any · Fig. 1 CONSORT
16 (24.6%) Discontinued study treatment 5 (7.7%) Adverse event
- aleniglipron 90 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 90 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 90 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 90 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 90 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
- aleniglipron 120 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
- aleniglipron 120 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
- aleniglipron 120 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
- aleniglipron 120 mg · disc_any · Fig. 1 CONSORT
14 (21.9%) Discontinued study treatment 7 (10.9%) Adverse event
- aleniglipron 120 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
- aleniglipron 120 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
- aleniglipron 120 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
- aleniglipron 120 mg · hba1c · Extended Data Table 5
Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
- aleniglipron 120 mg · sbp · Extended Data Table 5
Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: ACCESS (phase 2b). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/access/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.